AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.
